GUILLERMO MARIA
LOPEZ VIVANCO
Investigador/a en el periodo 2011-2020
Hospital de Cruces
Barakaldo, EspañaPublicaciones en colaboración con investigadoras/es de Hospital de Cruces (36)
2021
-
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 8
-
First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met
European Journal of Cancer, Vol. 159, pp. 174-181
-
Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
Cancer Chemotherapy and Pharmacology, Vol. 87, Núm. 4, pp. 543-553
-
Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy
Clinical Cancer Research, Vol. 27, Núm. 21, pp. 5878-5890
2020
-
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
The Lancet Oncology, Vol. 21, Núm. 11, pp. 1413-1422
2019
-
Germline c.1A>C heterozygous pathogenic variant in SDHA reported for the first time in a young adult with a gastric gastrointestinal stromal tumour (GIST): A case report
Hereditary Cancer in Clinical Practice, Vol. 17, Núm. 1
2018
-
Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS
Clinical and Translational Oncology, Vol. 20, Núm. 10, pp. 1261-1267
-
Infective endocarditis in a patient with metastatic colorectal cancer
Revista Espanola de Quimioterapia
-
Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: Results of the observational “LORENA” study
OncoTargets and Therapy, Vol. 11, pp. 5845-5852
2017
-
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
Journal of the National Cancer Institute, Vol. 109, Núm. 9
-
Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain
Clinical and Translational Oncology, Vol. 19, Núm. 12, pp. 1454-1461
-
Hereditary pancreatic cancer: Related syndromes and clinical perspective
Hereditary Cancer in Clinical Practice, Vol. 15, Núm. 1
2016
-
147P: Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study
Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. S122
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
-
Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: A retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study
Melanoma Research, Vol. 26, Núm. 3, pp. 278-283
2015
-
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
Scientific Reports, Vol. 5
-
Coste del tratamiento del cáncer de mama por estadío clínico en el País Vasco
Revista Espanola de Salud Publica, Vol. 89, Núm. 1, pp. 93-97
-
Efficacy and safety of fixed-dose-rate infusions of gemcitabine plus erlotinib for advanced pancreatic cancer
Journal of Analytical Oncology, Vol. 4, Núm. 1, pp. 44-51
-
Supervised physical exercise to improve the quality of life of cancer patients: The Eficancer randomised controlled trial
BMC Cancer, Vol. 15, Núm. 1
2014
-
A new biomarker panel in bronchoalveolar lavage for an improved lung cancer diagnosis
Journal of Thoracic Oncology, Vol. 9, Núm. 10, pp. 1504-1512